Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis

被引:221
作者
De Stefano, Nicola [1 ]
Stromillo, Maria Laura [1 ]
Giorgio, Antonio [1 ]
Bartolozzi, Maria Letizia [2 ]
Battaglini, Marco [1 ]
Baldini, Mariella [2 ]
Portaccio, Emilio [3 ]
Amato, Maria Pia [3 ]
Sormani, Maria Pia [4 ]
机构
[1] Univ Siena, Dept Med Surg & Neurosci, I-53100 Siena, Italy
[2] Hosp Empoli, Neurol Unit, Empoli, Italy
[3] Univ Florence, Dept Neurol, Florence, Italy
[4] Univ Genoa, Dept Hlth Sci DISSAL, Genoa, Italy
关键词
APPEARING WHITE-MATTER; CEREBRAL ATROPHY; DISABILITY PROGRESSION; CLINICAL-RELEVANCE; MRI; DISEASE; NATALIZUMAB; LESIONS; 5-YEAR; TRIAL;
D O I
10.1136/jnnp-2014-309903
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective To assess whether it is feasible to establish specific cut-off values able to discriminate 'physiological' or 'pathological' brain volume rates in patients with multiple sclerosis (MS). Methods The study was based on the analysis of longitudinal MRI data sets of patients with MS (n=206, 87% relapsing-remitting, 7% secondary progressive and 6% primary progressive) and healthy controls (HC; n=35). Brain atrophy rates were computed over a mean follow-up of 7.5 years (range 1-12) for patients with MS and 6.3 years (range 1-12.5) for HC with the SIENA software and expressed as annualised per cent brain volume change (PBVC/y). A weighted (on the follow-up length) receiver operating characteristic analysis and the area under the curve (AUC) were used for statistics. Results The weighted PBVC/y was -0.51 +/- 0.27% in patients with MS and -0.27 +/- 0.15% in HC (p<0.0001). There was a significant age-related difference in PBVC/y between HC older and younger than 35 years of age (p=0.02), but not in patients with MS (p=0.8). The cutoff of PBVC/y, as measured by SIENA that could maximise the accuracy in discriminating patients with MS from HC, was -0.37%, with 67% sensitivity and 80% specificity. According to the observed distribution, values of PBVC/y as measured by SIENA that could define a pathological range were above -0.52% with 95% specificity, above -0.46% with 90% specificity and above -0.40% with 80% specificity. Conclusions Our evidence-based criteria provide values able to discriminate the presence or absence of 'pathological' brain volume loss in MS with high specificity. Such results could be of great value in a clinical setting, particularly in assessing treatment efficacy in MS.
引用
收藏
页码:93 / 99
页数:7
相关论文
共 39 条
[21]   Gray matter atrophy and disability progression in patients with early relapsing-remitting multiple sclerosis A 5-year longitudinal study [J].
Horakova, Dana ;
Dwyer, Michael G. ;
Havrdova, Eva ;
Cox, Jennifer L. ;
Dolezal, Ondrej ;
Bergsland, Niels ;
Rimes, Brett ;
Seidl, Zdenek ;
Vaneckova, Manuela ;
Zivadinov, Robert .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 2009, 282 (1-2) :112-119
[22]   Determinants of cerebral atrophy rate at the time of diagnosis of multiple sclerosis [J].
Jasperse, Bas ;
Minneboo, Arjan ;
de Groot, Vincent ;
Kalkers, Nynke F. ;
van Helden, Paul E. ;
Uitdehaag, Bernard M. J. ;
Barkhof, Frederik ;
Polman, Chris H. .
ARCHIVES OF NEUROLOGY, 2007, 64 (02) :190-194
[23]   FSL [J].
Jenkinson, Mark ;
Beckmann, Christian F. ;
Behrens, Timothy Ej. ;
Woolrich, Mark W. ;
Smith, Stephen M. .
NEUROIMAGE, 2012, 62 (02) :782-790
[24]  
KURTZKE JF, 1983, NEUROLOGY, V33, P1444, DOI 10.1212/WNL.33.11.1444
[25]   The relationship between inflammatory activity and brain atrophy in natalizumab treated patients [J].
Magraner, M. ;
Coret, F. ;
Casanova, B. .
EUROPEAN JOURNAL OF RADIOLOGY, 2012, 81 (11) :3485-3490
[26]   Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters [J].
Minneboo, A. ;
Jasperse, B. ;
Barkhof, F. ;
Uitdehaag, B. M. J. ;
Knol, D. L. ;
de Groot, V. ;
Polman, C. H. ;
Castelijns, J. A. .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2008, 79 (08) :917-923
[27]   The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis - A monthly MRI study after triple-dose gadolinium-DTPA [J].
Paolillo, A ;
Piattella, MC ;
Pantano, P ;
Di Legge, S ;
Caramia, F ;
Russo, P ;
Lenzi, GL ;
Pozzilli, C .
JOURNAL OF NEUROLOGY, 2004, 251 (04) :432-439
[28]   Clinical impact of early brain atrophy in clinically isolated syndromes [J].
Perez-Miralles, F. ;
Sastre-Garriga, J. ;
Tintore, M. ;
Arrambide, G. ;
Nos, C. ;
Perkal, H. ;
Rio, J. ;
Edo, M. C. ;
Horga, A. ;
Castillo, J. ;
Auger, C. ;
Huerga, E. ;
Rovira, A. ;
Montalban, X. .
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (14) :1878-1886
[29]   Natalizumab may reduce cognitive changes and brain atrophy rate in relapsingremitting multiple sclerosis: a prospective, non-randomized pilot study [J].
Portaccio, E. ;
Stromillo, M. L. ;
Goretti, B. ;
Hakiki, B. ;
Giorgio, A. ;
Rossi, F. ;
De Leucio, A. ;
De Stefano, N. ;
Amato, M. P. .
EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (06) :986-990
[30]   Relationship between inflammatory lesions and cerebral atrophy in multiple sclerosis [J].
Richert, ND ;
Howard, T ;
Frank, JA ;
Stone, R ;
Ostuni, J ;
Ohayon, J ;
Bash, C ;
McFarland, HF .
NEUROLOGY, 2006, 66 (04) :551-556